Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell ...
5don MSN
Nurix Therapeutics gains ground as Roche partnership targets growing B-cell blood cancer market
Nurix Therapeutics, Inc. NRIX stock is up during Monday’s premarket session as the company collaborates with Roche Holdings ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results